Redeye comments on the outcome of Cereno Scientific’s warrants of series TO2.
Benefitting from strong structural growth trends A value-creating M&A strategy Vision 2025 could i...
Endomines EGM was held on 26 September 2022 which resolved on a reverse share split through which fo...
Redeye comments on Alligator’s successful conclusion of the phase I trial with ATOR-1017.
Redeye raises its estimates following today’s 5G deal for Enea.
Redeye is positive about the newly signed IRS contract of SEK 806,000 with a returning customer.
Calmark är ett medicintekniskt bolag som utvecklar och säljer analysinstrument för patientnära diagn...
Redeye is encouraged by XMReality’s latest order from ABB as it validates XMReality’s growth strateg...
Redeye återkommer med sin syn på BioArctic efter de transformativa och tydligt positiva fas III-resu...
Redeye was taken aback when Netmore announced its breakthrough agreements with Yorkshire Water, pote...
Sales growth of 20%, EBITA margin 10% Will investigate the possibility to move to Main Market Trad...
Redeye är mycket positiva till nattens tydligt positiva top-line data från fas III-studien ”Clarity ...
Redeye yesterday attended Acuvi’s first Capital Markets Day.
Oil coming down, ~60% of material costs linked to oil Valuation now just 5% above 2020 trough level...
Redeye leaves a short comment on Lipum’s announcement of a CTA approval for the phase I trial with S...
XVIVO: A very sad day
Urb-it raised SEK 23.3m from a pre-committed circle of existing investors, including Fjärde AP-fonde...
PC och Access driver försäljningen Trots fallande PC-volymer fortsätter penetrationen av fingeravtry...
Försäljningen fortsätter växa under Q2. Utöver det är finansiering säkrad och prioritet framåt är yt...
Redeye views last week’s regulatory proposal in India as a minor event that will likely not affect e...
